Inflammatory bowel disease (IBD) is a complex condition that requires individualized care to meet the needs of the patient’s current disease state. With available medications sometimes causing serious side effects or losing their efficacy over time, many researchers have been exploring new, more targeted ways of delivering medications or other beneficial compounds, such as probiotics.

To address pitfalls in IBD treatment and drug delivery, the labs of Juliane Nguyen, PhD, professor and vice chair of pharmacoengineering and molecular pharmaceuticals at the UNC Eshelman School of Pharmacy, and Janelle Arthur, PhD, associate professor of microbiology and immunology at the UNC School of Medicine, have developed a genetically engineered probiotic strain of Saccharomyces boulardii… Continue reading.